Exclusion Criteria
HbA1c ≥8.0%.Active liver disease, acute cerebrovascular disease, cardio-renal insufficiency, drug abuse or dependence, muscle injury, peripheral artery disease, ischemic stroke, myopathy, diabetes
INFECTIOUS DISEASES, PERIPHERAL ARTERY DISEASE, ACUTE CEREBROVASCULAR DISEASE, DISEASES, DYSFUNCTION, ISCHEMIC STROKE, HYPERTHYROIDISM, TRANSIENT ISCHEMIC ATTACKS, MYOPATHY, HYPOTHYROIDISM, ASCVD, DIABETES
Known ASCVD including CHD, ischemic stroke, transient ischemic attacks, peripheral artery disease, etc.Use of lipid-lowering drugs within 3 months prior to enrollment.Uncontrolled diabetes with HbA1c ≥8.0%.Active liver disease or dysfunction including sustained serum transaminase elevation of unknown reason or higher than three-fold of the upper limit of normal.Known myopathy or serum creatine kinase >5-fold of the upper limit of normal not caused by muscle injury.Contraindication to xuezhikang capsules, pravastatin, long-term use of glucocorticoids or contraceptives.At the acute stage of infectious diseases, or with any one of the following diseases: hyperthyroidism, hypothyroidism, acute cerebrovascular disease, severe cardio-renal insufficiency (glomerular filtration rate <60 mL/min/1.73mA history of alcohol or drug abuse or dependence within 3 months before inclusion in the trial.Participation in clinical trials of other drugs within 3 months before inclusion in the trial.Other conditions that make it inappropriate for participation at the investigator's discretion.